Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

Andreas Koster, Bruce Spiess, Derek P. Chew, Thomas Krabatsch, Luc Tambeur, Abelardo DeAnda, Roland Hetzer, Hermann Kuppe, Nicholas G. Smedira, A. Michael Lincoff

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalAmerican Journal of Cardiology
Volume93
Issue number3
DOIs
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Coronary Artery Bypass
Heparin
Blood Transfusion
Anticoagulants
Pharmacokinetics
bivalirudin
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. / Koster, Andreas; Spiess, Bruce; Chew, Derek P.; Krabatsch, Thomas; Tambeur, Luc; DeAnda, Abelardo; Hetzer, Roland; Kuppe, Hermann; Smedira, Nicholas G.; Lincoff, A. Michael.

In: American Journal of Cardiology, Vol. 93, No. 3, 01.02.2004, p. 356-359.

Research output: Contribution to journalArticle

Koster, Andreas ; Spiess, Bruce ; Chew, Derek P. ; Krabatsch, Thomas ; Tambeur, Luc ; DeAnda, Abelardo ; Hetzer, Roland ; Kuppe, Hermann ; Smedira, Nicholas G. ; Lincoff, A. Michael. / Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. In: American Journal of Cardiology. 2004 ; Vol. 93, No. 3. pp. 356-359.
@article{e19c30f9b88c4faa95422894df8a515c,
title = "Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting",
abstract = "We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.",
author = "Andreas Koster and Bruce Spiess and Chew, {Derek P.} and Thomas Krabatsch and Luc Tambeur and Abelardo DeAnda and Roland Hetzer and Hermann Kuppe and Smedira, {Nicholas G.} and Lincoff, {A. Michael}",
year = "2004",
month = "2",
day = "1",
doi = "10.1016/j.amjcard.2003.10.021",
language = "English (US)",
volume = "93",
pages = "356--359",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

AU - Koster, Andreas

AU - Spiess, Bruce

AU - Chew, Derek P.

AU - Krabatsch, Thomas

AU - Tambeur, Luc

AU - DeAnda, Abelardo

AU - Hetzer, Roland

AU - Kuppe, Hermann

AU - Smedira, Nicholas G.

AU - Lincoff, A. Michael

PY - 2004/2/1

Y1 - 2004/2/1

N2 - We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.

AB - We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.

UR - http://www.scopus.com/inward/record.url?scp=10744225946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744225946&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2003.10.021

DO - 10.1016/j.amjcard.2003.10.021

M3 - Article

C2 - 14759391

AN - SCOPUS:10744225946

VL - 93

SP - 356

EP - 359

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -